TY  - JOUR
AU  - Eron, Joseph J
AU  - Orkin, Chloe
AU  - Cunningham, Douglas
AU  - Pulido, Federico
AU  - Post, Frank A
AU  - De Wit, Stéphane
AU  - Lathouwers, Erkki
AU  - Hufkens, Veerle
AU  - Jezorwski, John
AU  - Petrovic, Romana
AU  - Brown, Kimberley
AU  - Van Landuyt, Erika
AU  - Opsomer, Magda
PY  - 2019
DO  - 10.1016/j.antiviral.2019.104543
UR  - http://hdl.handle.net/10668/14218
T2  - Antiviral research
AB  - Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic...
LA  - en
PB  - Elsevier
KW  - Darunavir/cobicistat/emtricitabine/TAF
KW  - Efficacy
KW  - Safety
KW  - Single-tablet regimen
KW  - Switch study
KW  - Adenine
KW  - Adult
KW  - Aged
KW  - Alanine
KW  - Anti-HIV agents
KW  - Cobicistat
KW  - Darunavir
KW  - Drug combinations
KW  - Drug substitution
KW  - Emtricitabine
KW  - Emtricitabine, tenofovir disoproxil fumarate drug combination
KW  - Female
KW  - HIV infections
KW  - HIV-1
KW  - Humans
KW  - Male
KW  - Middle aged
KW  - Protease inhibitors
KW  - Sustained virologic response
KW  - Tablets
KW  - Tenofovir
KW  - Treatment outcome
KW  - Viral Load
TI  - Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
TY  - Research article
VL  - 170
ER  -